Adverum Biotechnologies Cuts Workforce, Prioritizes ADVM-022

Adverum Biotechnologies Inc  (NASDAQ: ADVM ) announced a restructuring plan , including reductions in headcount and expenses, to prioritize its clinical development of ADVM-022, a single intravitreal injection for wet age-related macular degeneration (AMD). Adverum intends these restructuring measures to fully support its ADVM-022 development plan, providing it with ... Full story available on Benzinga.com